Rodman & Renshaw initiated coverage of Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG) with a Buy rating and a $10 price target sending the stock price soaring $1.82 to close at $3.52.
Eyegate Pharmaceuticals initiated with Buy
February 01, 2016 at 18:22 PM EST
